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Eﬀ ect of urgent treatment for transient ischaemic attack and 
minor stroke on disability and hospital costs (EXPRESS study): 
a prospective population-based sequential comparison
Ramon Luengo-Fernandez, Alastair M Gray, Peter M Rothwell 
Summary 
Background Evidence is available on the eﬀ ectiveness and costs of treatments to reduce stroke risk in long-term 
secondary prevention. However, there are few data on the costs and outcomes of urgent assessment and treatment 
after the onset of transient ischaemic attack (TIA) or minor stroke. The Early use of eXisting PREventive Strategies for 
Stroke (EXPRESS) study showed that urgent assessment and treatment reduced the 90-day risk of recurrent stroke by 
about 80%. We now report the eﬀ ect of the EXPRESS intervention on admissions to hospital, costs, and disability.
Methods EXPRESS was a prospective population-based before (phase 1: April 1, 2002, to Sept 30, 2004) versus after 
(phase 2: Oct 1, 2004, to March 31, 2007) study of the eﬀ ect of early assessment and treatment of TIA or minor stroke 
on the risk of early recurrent stroke. This report assesses the eﬀ ect of the introduction of the phase 2 clinic on 
admissions to hospital within 90 days, hospital bed-days, hospital costs, and 6-month new disability (progression 
from no disability before event [modiﬁ ed Rankin scale score ≤2 points] to disability at 6 months [modiﬁ ed Rankin 
scale score >2 points]) or death, compared with the phase 1 clinic. To assess the main predictors of these outcomes, 
multivariate regression analyses were done.
Findings The 90-day risk of fatal or disabling stroke was reduced in phase 2 (1 of 281 vs 16 of 310; p=0·0005). Hospital 
admissions for recurrent stroke were also lower in phase 2 than in phase 1 (5 vs 25; p=0·001), which reduced the overall 
number of hospital bed-days compared with phase 1 (672 vs 1957 days; p=0·017). Hospital bed-days for admissions to 
hospital due to vascular causes were also lower in phase 2 (427 vs 1365 days; p=0·016), which generated savings of £624 
per patient referred to the phase 2 clinic (p=0·028). Results from the multivariate analyses showed that assessment in 
phase 2 was an independent predictor of reduced disability, days in hospital, and costs. 
Interpretation Urgent assessment and treatment of patients with TIA or minor stroke who were referred to a specialist 
outpatient clinic reduced subsequent hospital bed-days, acute costs, and 6-month disability. 
Funding UK Department of Health; UK Medical Research Council; Dunhill Medical Trust; Stroke Association; BUPA 
Foundation; National Institute for Health Research; Thames Valley Primary Care Research Partnership; Oxford 
Partnership Comprehensive Biomedical Research Centre.
Introduction
Stroke is the second leading cause of death worldwide; it 
accounts for 10% of total deaths,1 and is one of the main 
reasons for use of health-care resources2 at an annual cost 
to the UK health-care system of £4·6 billion.3 Treatments 
have been developed to prevent recurrent strokes in the 
long term after a transient ischaemic attack (TIA) or minor 
stroke;4–8 appropriate interventions are predicted to reduce 
the long-term risk of recurrent stroke by as much as 
80–90%.9 However, although the risk of recurrent stroke is 
8–10% during the 7 days after a TIA or minor stroke,10–12 
until recently there were no reliable estimates of the 
eﬀ ectiveness, let alone costs, of rapid assessment and acute 
treatment for such patients. In the UK, which has relatively 
low rates of hospital admissions for TIA and minor stroke,13 
this could entail emergency access to outpatient specialist 
care because about half of all patients currently wait more 
than 14 days to be assessed and treated.14
The aim of the Early use of eXisting PREventive 
Strategies for Stroke (EXPRESS) study was to measure the 
eﬀ ect of more rapid treatment after TIA and minor stroke 
in patients who were not admitted directly to hospital.15 
EXPRESS was a rigorous observational study of the phased 
introduction of urgent assessment and treatment, nested 
within a population-based study of all incident and 
recurrent TIA and stroke in Oxfordshire, UK (the Oxford 
Vascular Study [OXVASC]).16 During phase 1 of OXVASC, 
a daily TIA and minor stroke clinic was introduced, to 
which collaborating primary-care physicians referred most 
patients with suspected TIA or minor stroke. The clinic 
was appointment based, and there were inherent delays in 
receiving referrals and contacting patients; furthermore, 
instead of initiating treatment, the clinic only made 
treatment recommendations to the referring primary-care 
physicians. After 30 months, the clinic was changed to a 
“no appointment necessary” clinic, to which primary-care 
physicians were asked to send all patients immediately 
after presentation for TIA or minor stroke, and treatment 
was initiated immediately if the diagnosis was conﬁ rmed 
(phase 2). The EXPRESS study showed that the 90-day risk 
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of recurrent stroke fell by about 80% in patients who were 
referred to the phase 2 clinic compared with those referred 
to the phase 1 clinic (10·3% in phase 1 vs 2·1% in phase 2; 
p=0·0001). This beneﬁ t was independent of age and sex, 
and early treatment did not increase the risk of major 
bleeding. Similar low risks of recurrent stroke with urgent 
assessment and treatment have also been reported in the 
SOS-TIA study.17
The objective of this study was to assess to what extent 
the reduction in recurrent stroke risk in phase 2 of 
EXPRESS, compared with phase 1, reduced admissions to 
hospital, the number of bed-days, costs associated with 
admission to hospital, and disability in those patients 
referred to the EXPRESS TIA and minor stroke outpatient 
clinic. This information will supply health-care providers 
with the necessary data to consider a similar service 
provision for patients with TIA and minor stroke. 
Methods
Patients
The methods of OXVASC and EXPRESS have been 
reported previously.15,16 The OXVASC study population 
comprised about 91 000 individuals who were registered at 
nine primary-care practices across Oxfordshire, UK. 
Registration of patients into the study began on April 1, 2002 
(phase 1). Informed, formal, written consent was obtained 
from all patients included in the analyses. 
Procedures
The EXPRESS study was a population-based sequential 
comparison study nested within OXVASC. Phase 1 ran 
from April 1, 2002, to Sept 30, 2004, during which time 
primary-care physicians referred any patient who was 
suspected of having a TIA or non-disabling stroke to the 
study clinic. The OXVASC team then contacted the patient 
to arrange a clinic appointment as quickly as possible. 
After clinic assessment and investigation, the general 
practitioner was faxed a report that included any treatment 
recommendations. In phase 2 (Oct 1, 2004, to 
March 31, 2007), the mode of access to the outpatient clinic 
was changed, and treatment was initiated in the clinic. 
Primary-care physicians were requested to send all patients 
directly to the study clinic immediately after they presented 
for medical attention, with no need to prearrange referral, 
and treatment was initiated immediately in the clinic. In 
both phases, the study clinician recorded detailed clinical 
information and the modiﬁ ed Rankin scale (mRS) score18 
before the event. Neurological impairment was measured 
with the National Institutes of Health stroke scale 
(NIHSS),19 to assess the severity of an event at baseline. As 
reported previously,15 the protocols for investigation and 
the treatments recommended were identical in both 
phases of the study, except that treatment was initiated in 
the study clinic in phase 2.
All patients were followed up by a research nurse or 
clinical research fellow at 1 and 6 months after the index 
event, and patients were asked about any new neurological 
symptoms or any bleeding that required medical attention, 
with patients being reassessed with the mRS. Recurrent 
vascular events were also identiﬁ ed acutely by overlapping 
methods of hot and cold pursuit.20 All patients with 
possible recurrent strokes were reassessed by a study 
neurologist (PMR or colleagues),15 who prepared a detailed 
clinical report of the event and related investigations. 
These reports were all reviewed at the end of the study by 
an independent neurologist who was blind to the phase of 
the study in which the event occurred and who decided 
which events were deﬁ nite recurrent strokes.15
Statistical analysis
The primary analysis included all patients with TIA or 
stroke referred to the EXPRESS study clinic until March 31, 
2007 (ie, during phases 1 and 2 of the EXPRESS study), 
with follow-up to June 30, 2007. A sensitivity analysis was 
also done for all patients with TIA or minor stroke (NIHSS 
score ≤3 points) in the whole OXVASC population, 
irrespective of whether they were referred to the EXPRESS 
study clinic or to other services. 
As was detailed in the original report of the EXPRESS 
study,15 the exclusion of patients from the analysis in 
phase 2 if they had also presented in phase 1 could have 
caused bias (patients were not excluded from phase 1 if 
they had an event before the study); therefore, patients 
who presented in both phases were included in both 
analyses. The same approach was used in this study. To 
avoid any possible bias due to carry-over eﬀ ects of 
improved long-term treatment in phase 1 (compared 
with treatment before the study) on outcome of any 
subsequent events in phase 2, all analyses in the original 
report of the EXPRESS study were also done for incident 
ﬁ rst-ever events only. However, because there were no 
qualitative diﬀ erences between these analyses and the 
overall results, analysis of only incident events was not 
repeated in this study.
The primary outcome in the EXPRESS study was the 
90-day risk of recurrent stroke.15 Outcome measures 
included in this further analysis were hospital admissions, 
days in hospital, total costs of admission to hospital during 
the 90 days after the event, and new patient disability or 
death. For any patient who was admitted to hospital before 
the 90-day follow-up but who was in hospital beyond this 
time period, length of stay was estimated until hospital 
discharge. All-cause admissions to hospital (ie, for TIA, 
stroke, or other vascular and non-vascular diseases) and 
hospital bed-days were assessed. For admissions to 
hospital due to vascular reasons, a more in-depth analysis 
was done by examination of overall days in hospital, length 
of stay conditional on admission, and costs, stratiﬁ ed by 
those incurred by recurrent stroke and those incurred by 
other vascular causes. Our study, however, did not include 
the costs of setting up the outpatient clinics for the urgent 
assessment and treatment of TIA and minor stroke. 
Because the phase 2 clinic was nested within the ongoing 
OXVASC study, which already operated a daily study clinic, 
Articles
www.thelancet.com/neurology   Vol 8   March 2009 237
it was not possible to quantify the additional costs required 
to set up these clinics.
Disability was assessed at 6 months and was deﬁ ned as 
an mRS score between 3 and 5 points. Because patients 
could have been disabled before their index event, new 
disability combined with death at 6 months was also 
assessed. New disability was deﬁ ned as the progression 
between no disability before event (ie, pre-event mRS score 
<3 points) to disability 6 months after index event (ie, 
6-month mRS score >2 points).
Admissions to hospital, day cases, and length of stay 
were derived from central administrative sources, patients’ 
records, and direct questioning at follow-up, which 
provided information on the dates of admission and 
discharge, and on patient transfers between specialty 
wards. The causes of admission to hospital were 
investigated by hot pursuit or by matching event dates to 
admission dates, linking of hospital information with 
discharge coding, and by a review of hospital notes by the 
OXVASC senior neurologist (PMR). Unit costs were 
obtained from national reference costs and calculated for 
each day spent in each specialty ward.13,21,22 Costs were 
standardised to 2005–06 prices by use of the UK National 
Health Service hospital and community health services 
inﬂ ation index. Unit costs, length of stay by ward type, and 
number of day cases in each phase of EXPRESS are 
reported in webtables 1 and 2. 
Categorical outcomes, including admissions to hospital 
and disability, are reported as proportions, and exact 
95% CIs were calculated. In addition, for these variables, 
the size of eﬀ ect was reported as an odds ratios with 
95% CIs. Statistical diﬀ erences for categorical variables 
were evaluated with standard χ² tests. Hospital bed-days 
and costs were reported as means. To account for the 
skewed resource use and cost data, 95% CIs were calculated 
non-parametrically from 10 000 bootstrap estimates.23
To assess the main predictors of hospital vascular 
admission—hospital bed-days and total costs—a two-part 
model was used. A logistic regression model was used to 
assess the predictors of admission to hospital. Conditional 
on admission, a general gamma linear model assuming a 
log identity was used to determine baseline predictors of 
length of stay and costs of hospital admission at the 90-day 
follow-up.24 Logistic multivariate analyses were done to 
assess prognostic indicators of new disability or death, and 
overall disability or death, at 6 months. For the multivariate 
analysis of new disability or death, those patients who were 
already disabled before their index event were excluded 
from the analysis because the main objective was to record 
progression from either no baseline disability to disability 
or death, or baseline disability to death, 6 months after the 
event. Baseline predictors are sex; age; previous history of 
myocardial infarction, angina, peripheral vascular disease, 
hypertension, stroke, or diabetes; smoking status; age at 
which the patient left education; event type (TIA or stroke); 
stroke severity (NIHSS score); and disability before the 
event (mRS of 3 to 5 points). Both age and NIHSS score 
were included in the analyses as categorical variables 
because of observed non-linear eﬀ ects on outcomes, 
resource use, and costs.13 Further regression models were 
done that included age and NIHSS score as continuous 
variables, and by including the quadratic terms of age and 
NIHSS score. The results showed that the models were 
best speciﬁ ed when age and NIHSS score were included 
as categorical variables. Statistical signiﬁ cance was set at 
p<0·05. Diagnostic tests to check for model speciﬁ cation 
were done with Preigbon’s link test. 
To assess the consequences of a decrease in the 
eﬀ ectiveness of the phase 2 clinic on hospital bed-days and 
Phase 1 Phase 2 Total
Whole population 634 644 1278
Direct inpatient referral 285 322 607
Discharged from accident and 
emergency department
33 54 87
Inpatient care 252 268 520
Referral to outpatient care 323 297 620
Referred direct to EXPRESS clinic 310 281 591
Referred to other clinics ﬁ rst 13 16 29
Not referred to secondary care 26 25 51
Patients are stratiﬁ ed by place of initial referral.
Table 1: Patients who sought medical attention after ﬁ rst event
Phase 1 
(n=310)
Phase 2 
(n=281)
Age (years)
<80 207 (67%) 189 (67%)
≥80 103 (33%) 92 (33%)
Men 141 (45%) 132 (47%)
Previous myocardial infarction 36 (12%) 37 (13%)*
Previous peripheral vascular disease 18 (6%) 20 (7%)*
Previous angina 57 (18%) 42 (15%)*
Hypertension 167 (54%) 164 (58%)*
Previous stroke 55 (18%) 41 (15%)*
Diabetes 36 (12%) 37 (13%)*
Smoking status
Never 143 (46%) 118 (42%)*
Ex-smoker 125 (40%) 120 (43%)
Current 42 (14%) 41 (15%)
Baseline mRS 1 (0–2·0) 1 (0–1·5)*
Previous treatment with antiplatelet drugs 139 (45%) 109 (39%)†
Previous treatment with a statin 63 (20%) 89 (32%)†
Age left education (years) 16 (3) 17 (3)
Acute event
TIA 156 (50%) 160 (57%)
Stroke 154 (50%) 121 (43%)
NIHSS score 0 (0–1) 0 (0–1)*
Data are n (%), mean (SD), or median (IQR). *1 patient missing. †2 patients missing.
Table 2: Baseline characteristics for patients referred to the EXPRESS 
clinics
See Online for webtables 1 and 2
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hospital costs, the 80% reduction in recurrent stroke risk 
achieved by urgent assessment and treatment in the 
phase 2 clinic was reduced to 40% (ie, half the eﬀ ectiveness). 
We assumed that the observed relations between 
reductions in recurrent stroke risk during phase 2 and the 
eﬀ ect on length of stay and costs would be the same. 
Although most TIA and minor strokes were referred to 
the EXPRESS study clinic, a proportion of patients with 
TIA and minor stroke (NIHSS score ≤3 points) were 
managed by their primary-care physicians, referred to 
hospital-based care, or referred to other specialist clinics. 
A further sensitivity analysis was therefore done that 
included all patients with TIA and minor stroke who were 
not referred to the EXPRESS clinic. For this analysis, we 
compared the number of recurrent strokes, progression to 
disability or death, number of admissions to hospital due 
to vascular causes, hospital bed-days because of vascular 
admissions, and associated costs of admission to hospital 
in phase 1 with those in phase 2, using the methods 
described above. 
Role of the funding source
None of the agencies that funded OXVASC had any input 
into the design, performance, analysis, or reporting of 
either the OXVASC or EXPRESS studies, nor did they see 
the manuscript before ﬁ nal acceptance for publication. 
RL-F, AMG, and PMR had access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit the manuscript for publication.
Results
In the whole OXVASC population, 634 patients sought 
medical attention after TIA or stroke in phase 1 and 644 in 
phase 2 (ie, 1278 ﬁ rst presentations, with 66 patients 
seeking medical attention after an event in both phases). 
607 presentations (285 in phase 1 and 322 in phase 2) were 
made directly to emergency services or were patients who 
were already in hospital at the time of stroke. Of the 
620 patients with TIA or stroke who were referred to 
outpatient services, 591 (95%) were referred direct to the 
study clinic (310 in phase 1 and 281 in phase 2), and are the 
sample in our primary analysis (table 1). 
Baseline characteristics and risk factors of the patients, 
which have been reported elsewhere,15 were generally 
similar in the two phases of the study (table 2), including 
education levels (p=0·39) and mRS scores (p=0·13). The 
median (IQR) NIHSS score for the patients with minor 
strokes (ie, excluding patients with TIA) at the time of 
assessment in the study clinic was 1 (0–3) point in both 
study periods; 236 (86%) patients had NIHSS scores of 
3 points or less and 264 (96%) had NIHSS scores of 
5 points or less.
 EXPRESS showed that attendance at the phase 2 clinic 
signiﬁ cantly reduced the number of 90-day recurrent 
strokes compared with attendance at the phase 1 clinic 
(6 of 281 [2%] vs 32 of 310 [10%]; p=0·0001). In addition, 
data from this new analysis show that attendance at the 
phase 2 clinic signiﬁ cantly reduced the number of 
recurrent fatal strokes compared with attendance at the 
phase 1 clinic (1 of 281 [<1%] vs 8 of 310 [3%]; p=0·027), 
the number of disabling strokes (0 of 281 [0%] vs 8 of 310 
[3%]; p=0·007), and, overall, the number of fatal or 
disabling strokes (1 of 281 [<1%] vs 16 of 310 [5%]; 
p=0·0005). For all patients in the EXPRESS study, at 
6 months after the index event, 14 of 310 patients (5%) in 
phase 1 and 9 of 281 patients (3%) in phase 2 had died 
(p=0·410). There were no diﬀ erences in the proportion of 
Phase 1 
(n=310)
Phase 2 
(n=281)
p
All admissions to hospital 57 (18%) 50 (18%) 0·85
Non-vascular admissions to hospital 9 (3%) 12 (4%) 0·37
Vascular admissions to hospital 48 (15%) 38 (14%) 0·50
Carotid surgery 9 (3%) 10 (4%) 0·65
Hospital admissions owing to event 
complications
11 (4%) 18 (6%) 0·11
Recurrent stroke* 25 (8%) 5 (2%) 0·001
Angiography 0 2 (1%) 0·23†
Coronary heart disease 3 (1%) 1 (<1%) 0·63†
Peripheral vascular disease 0 2 (1) 0·23†
Total number of bed-days 1957 672 ··
Bed-days per patient 6 (24) 2 (11) 0·02
Data are n (%) or mean (SD). *As part of these admissions to hospital one patient 
in each phase had carotid surgery. †Fisher’s exact test. 
Table 4: All-cause hospital admission and bed-days during the 90-day 
follow-up
New disability or death* Overall disability or death†
Adjusted 
odds ratio 
95% CI p value Adjusted 
odds ratio
95% CI p value
Phase 2 0·55 0·31–0·96 0·03 0·58 0·34–0·98 0·04
Age 65–74 years 1·65 0·66–4·12 0·28 1·32 0·57–3·04 0·52
Age ≥75 years 2·79 1·18–6·58 0·02 2·01 0·93–4·34 0·08
Male 0·63 0·35–1·11 0·11 0·84 0·49–1·46 0·55
Stroke 1·35 0·77–2·40 0·30 0·91 0·52–1·58 0·74
Hypertension 0·87 0·50–1·52 0·62 0·62 0·35–1·06 0·08
Diabetes 0·77 0·29–2·04 0·60 1·03 0·45–2·38 0·94
Previous stroke 1·94 0·98–3·86 0·06 1·71 0·89–3·30 0·11
Previous myocardial 
infarction
1·04 0·41–2·68 0·93 0·77 0·32–1·85 0·56
Previous angina 0·79 0·34–1·80 0·57 0·90 0·41–1·99 0·79
Previous PVD 2·03 0·75–5·45 0·16 2·44 0·94–6·34 0·07
Previous disability ·· ·· ·· 27·64 14·07–54·30 <0·0001
Ex-smoker 1·02 0·56–1·86 0·94 1·00 0·57–1·77 0·99
Current smoker 0·70 0·26–1·93 0·49 0·78 0·31–2·01 0·61
NIHSS >3 points 3·54 1·48–8·45 0·004 4·01 1·69–9·51 0·002
Age left education 0·93 0·85–1·03 0·16 0·93 0·84–1·02 0·13
Constant 1·00 ·· ·· 1·00 ·· ··
*Phase 1, n=264; phase 2, n=252. †Phase 1, n=310; phase 2, n=278. PVD=peripheral vascular disease. NIHSS=National 
Institutes of Health stroke scale. ··=not applicable.
Table 3: Predictors of new disability or death and of overall disability or death by multivariate analysis
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patients who changed from disability at baseline to no 
disability at 6 months; eight patients in each phase had 
improvements in this way (p=0·831). However, a higher 
proportion of patients progressed from no disability at 
baseline to disability at 6 months in phase 1 than in 
phase 2 (33 of 310 [11%] vs 16 of 281 [6%], p=0·031; 
unadjusted odds ratio [OR] 0·46, 95% CI 0·25–0·86). 
Therefore, in phase 1, 47 of 310 patients (15%) had either 
died or become disabled since their initial event, 
compared with 25 of 281 patients (9%) in phase 2 
(OR 0·51, 95% CI 0·30–0·85; p=0·022). 
Multivariate regression analyses were done to assess the 
baseline predictors of death or new disability and those of 
death or overall disability (table 3). Event severity, as 
assessed by an NIHSS score greater than 3 points, 
(p=0·004) and being 75 years or older (p=0·02) were 
predictors of death or new disability at 6 months, after 
controlling for other baseline characteristics in the 
multivariate analysis. Assessment during phase 2 was 
signiﬁ cantly associated with reduced new disability or 
death (p=0·03). Similarly, assessment in phase 2 was 
associated with reduced death or overall disability at 
6 months (p=0·04). Event severity assessed by NIHSS 
score greater than 3 points (p=0·002) and previous 
disability (p<0·0001) were signiﬁ cantly associated with 
increased overall disability or death, after controlling for 
baseline characteristics in the multivariate analysis 
(table 3).
57 of 310 patients (18%) who were referred to the study 
clinic in phase 1 were admitted to hospital during the 
90-day follow-up period, compared with 50 of 281 patients 
(18%) during phase 2 (p=0·85; table 4). No signiﬁ cant 
diﬀ erences in reasons for admission to hospital were 
found between phases, except for recurrent strokes: 
25 of 310 patients (8%) in phase 1 compared with 5 of 
281 patients (2%) in phase 2 (OR 0·21, 95% CI 0·88–0·55; 
p=0·001). There were substantially fewer bed-days in 
phase 2 than in phase 1: 672 bed-days in phase 2 compared 
with 1957 bed-days in phase 1 (table 4), which translated 
into an average reduction of four (95% CI –8 to –1; p=0·02) 
hospital bed-days per patient referred to the clinic in 
phase 2 compared with phase 1. 
The number of days in hospital due to any vascular 
disease was lower in phase 2 than in phase 1 
(427 vs 1365 days, respectively; a mean reduction of 
3 days per patient, 95% CI –6 to –1; p=0·02). Table 5 shows 
that the reduction in days in hospital during phase 2 was 
driven by reductions in days in hospital due to recurrent 
stroke, whereas days in hospital because of other vascular 
causes did not vary signiﬁ cantly between phases. 
Conditional on hospital admission, the length of stay for 
patients who were admitted in phase 1 was 29 (SD 52) days 
compared with 11 (11) days for those admitted in phase 2, 
which is a reduction of 18 days (95% CI –36 to –4; p=0·02) 
per patient. Furthermore, patients who had recurrent 
stroke in phase 2 had shorter stays than did those who had 
recurrent stroke in phase 1; the mean length of stay was 
15 (29) days in phase 2 compared with 32 (60) days in 
phase 1, a non-signiﬁ cant mean reduction of 17 days 
(–46 to 20; p=0·37). 
Because the study clinics in phase 1 and phase 2 were 
undertaken over diﬀ erent time periods, external factors 
could explain some of the diﬀ erences in length of stay 
between phases. Hospital admissions for the 607 patients 
who attended emergency services and were referred 
directly for inpatient treatment or were in hospital at the 
time of event were, therefore, also assessed. There were no 
diﬀ erences in length of stay between the two phases 
(31 days; p=0·89), which suggests that unmeasured 
temporal trends did not aﬀ ect the length of overall hospital 
stay during the two time periods. 
Table 5 shows the average hospital costs incurred as a 
result of vascular causes in each phase. In phase 1, the 
average costs per patient were £1056 (SD £4879) compared 
with £432 (£2277) in phase 2, a reduction of £624 (95% CI 
£1370 to £104; p=0·03) per patient. The reduction in 
hospital costs during phase 2 was generated by substantial 
reductions in costs due to recurrent stroke. For patients 
with recurrent stroke, the mean hospital cost incurred 
(total cost of recurrent stroke averaged by number of 
patients who had recurrent stroke [n=38]) was £7449 
(£12 444) in phase 1 compared with £3560 (£6394) in 
phase 2, an average reduction of £3888 (–£9937 to £4087; 
p=0·326). 
Most patients (484 of 591 [82%]) were not admitted to 
hospital, and therefore did not incur any hospital-related 
costs. A two-part regression model was used to ascertain 
the baseline predictors of hospital admission for vascular 
Phase 1 (n=310) Phase 2 (n=281) Diﬀ erence (phase 2–phase 1) p
Total days in hospital 1365 427 –938 0·02*
Days in hospital because of recurrent stroke 1147 90 –1057 0·005*
Days in hospital because of other vascular disease 218 337 119 0·31*
Total costs (£) 327 474 121 506 –205 968
Mean costs (£) 1056 (4879) 432 (2277) –624 (–1370 to –104) 0·03
Recurrent stroke (£) 866 (4788) 76 (998) –790 (–1425 to –328) 0·003
Other vascular cause (£) 191 (1102) 356 (2508) 166 (–64 to 497) 0·19
Data are n, mean (SD), or diﬀ erence (95% CI). *To obtain p values, the total number of days in hospital was averaged by the total patient sample.
Table 5: Total days in hospital and total costs per patient for admissions for TIA, stroke, or other vascular disease
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reasons (if patients incurred hospital-related costs), 
hospital bed-days, and hospital-related costs (table 6). A 
history of peripheral vascular disease (p=0·005) and 
severity of stroke (p<0·0001), deﬁ ned as an NIHSS score 
higher than 3 points, were predictors of overall hospital 
admission, after controlling for baseline characteristics in 
the multivariate analysis. Results from the multivariate 
analysis also showed that, conditional on hospital 
admission, attendance at the phase 2 clinic was signiﬁ cantly 
associated with reduced length of stay and hospital-related 
costs, whereas premorbid disability was signiﬁ cantly 
associated with increased length of stay and hospital-
related costs (table 6). 
Of the 1278 (634 in phase 1 and 644 in phase 2) 
presentations for medical attention after TIA or stroke 
(table 1), 966 patients (476 in phase 1 and 490 in phase 2) 
sought medical attention for TIA or minor stroke, and 
the rest (312 patients [158 in phase 1 and 154 in phase 2]) 
sought medical attention for a more severe stroke. Of 
the 966 TIA or minor strokes, 620 (323 in phase 1 and 
297 in phase 2) were referred for outpatient assessment, 
of which 591 (95%) were referred to the EXPRESS 
clinics. The remaining 346 patients (153 in phase 1 and 
193 in phase 2) with TIA or minor stroke were referred 
elsewhere (mostly to an emergency department or 
directly to hospital for acute admission). A sensitivity 
analysis was done by including all patients with TIA and 
minor stroke, irrespective of whether or not they were 
referred to the EXPRESS clinic. This was done to identify 
whether attendance at the phase 2 EXPRESS clinic 
reduced progression to death or disability, admissions to 
hospital due to vascular causes, hospital bed-days, and 
associated costs for all patients with TIA or minor 
stroke.
476 patients with TIA or minor stroke (233 TIA, 
243 minor stroke) in phase 1 and 490 patients (251 TIA, 
239 minor stroke) in phase 2 sought medical attention. 
For this population, there were signiﬁ cantly fewer 90-day 
recurrent strokes in phase 2 than in phase 1 
(21 of 490 patients [4%] vs 53 of 476 patients [11%]; 
p=0·0004). Data on baseline or 6-month mRS scores 
were missing for 43 of 476 patients (9%) in phase 1 and 
46 of 490 patients (9%) in phase 2 (p=0·77). For patients 
with no missing mRS data, 85 of 433 (20%) in phase 1 
progressed to either death or new disability 6 months 
after the initial event, compared with 64 of 444 (14%) in 
phase 2 (p=0·04).
During phase 1, 139 of 476 patients (29%) were admitted 
to hospital for vascular reasons compared with 156 of 
490 patients (32%) in phase 2 (p=0·37). The number of 
days in hospital because of any vascular disease was 
lower in phase 2 than in phase 1 (4520 days vs 3728 days). 
When averaged across all patients, the mean number of 
hospital bed-days was 10 (SD 37) days in phase 1 compared 
with 8 (25) in phase 2, a mean reduction of 2 days (95% 
CI –6 to 2; p=0·176). Conditional on hospital admission, 
the average length of stay was 33 (62) days in phase 1 
compared with 24 (41) days in phase 2 (mean diﬀ erence 
–9 days, 95% CI –22 to 3; p=0·079). In phase 1, the mean 
costs of treatment in hospital were £2646 (£11 848) 
compared with £2124 (£6642) in phase 2, a non-signiﬁ cant 
diﬀ erence of –£522 (–£1989 to £554; p=0·13) per patient. 
For patients admitted to hospital, the mean cost was 
£9062 (£20 606) in phase 1 compared with £6670 (£10 425) 
in phase 2, a mean diﬀ erence of –£2392 (–£6684 to £791; 
p=0·10).
The main analysis of the EXPRESS study showed an 
80% reduction in recurrent stroke risk in phase 2 compared 
with phase 1. However, if we assume the same relation 
between reductions in recurrent stroke risk and hospital 
costs and bed-days, halving the eﬀ ectiveness rate of the 
phase 2 clinic (ie, a 40% reduction in stroke risk) would be 
associated with a 33% reduction in hospital bed-days 
(2·95 days vs 4·4 days in phase 1), and a 30% reduction in 
costs of hospital admission (£744 vs £1056 for phase 1). 
Discussion
In the UK, most patients with TIA or minor stroke are 
managed in weekly outpatient clinics after referral by a 
primary-care physician. This system results in about half 
of all patients waiting for more than 14 days to be assessed 
and treated,14 during which time the risk of recurrent 
stroke is at its highest. The EXPRESS study showed that 
urgent assessment of TIA and minor stroke in 
combination with early initiation of preventive treatment 
Hospital admission* Length of stay 
conditional on 
admission†
Total costs†
OR p Coeﬃ  cient p Coeﬃ  cient p
Phase 2 1·00 (0·61 to 1·65) 0·99 –0·84 0·01 –0·66 0·02
Age 65–74 years 1·56 (0·76 to 3·18) 0·23 –0·56 0·18 –0·54 0·15
Age >75 years 1·21 (0·58 to 2·51) 0·61 0·41 0·42 0·20 0·65
Men 1·13 (0·67 to 1·90) 0·65 –0·32 0·37 –0·32 0·31
Stroke 1·15 (0·68 to 1·94) 0·61 0·21 0·56 0·06 0·85
Hypertension 0·81 (0·48 to 1·35) 0·42 0·43 0·23 0·35 0·27
Diabetes 0·89 (0·41 to 1·93) 0·77 –0·10 0·866 –0·11 0·82
Previous stroke 0·53 (0·25 to 1·13) 0·10 0·67 0·22 0·59 0·22
Previous myocardial 
infarction
0·85 (0·35 to 2·05) 0·72 –0·87 0·13 –0·70 0·17
Previous angina 1·70 (0·80 to 3·62) 0·17 –0·12 0·84 –0·26 0·61
Previous PVD 3·30 (1·44 to 7·58) 0·005 0·25 0·59 0·20 0·61
Previous disability 1·89 (0·96 to 3·73) 0·07 0·85 0·04 0·77 0·03
Ex-smoker 0·56 (0·31 to 1·01) 0·06 0·32 0·42 0·27 0·44
Current smoker 1·70 (0·82 to 3·52) 0·15 –0·51 0·23 –0·61 0·11
NIHSS score >3 points 5·94 (2·72 to 12·96) <0·0001 0·29 0·50 0·22 0·55
Age left education 0·92 (0·83 to 1·01) 0·088 –0·03 0·63 –0·04 0·09
Constant 1·00 ·· 3·49 0·01 9·49 <0·0001
Data are adjusted odds ratio (95% CI). PVD=peripheral vascular disease. NIHSS=National Institutes of Health stroke 
scale. *Phase 1, n=310; phase 2, n=279. †Phase 1, n=48; phase 2, n=38. 
Table 6: Multivariate analyses of predictors of admission to hospital, subsequent length of stay, and 
total hospital costs
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reduced the risk of early recurrent stroke by about 80%.15 
This further analysis shows that, for patients referred to 
the EXPRESS study outpatient clinic, there were also 
reductions in fatal or disabling recurrent strokes, 90-day 
hospital bed-days, costs of admission to hospital, and 
overall disability levels at 6 months’ follow-up. 
Furthermore, those patients in phase 2 who had recurrent 
stroke spent less time in hospital, incurred lower costs, 
and had lower case fatality and new disability rates than 
the patients in phase 1; however, the number of 
recurrences during phase 2 was too small to assess the 
diﬀ erences reliably. 
We report that urgent assessment and treatment of TIA 
and minor stroke reduced the overall number of days in 
hospital and generated savings of £624 per patient referred 
to the clinic. The extrapolation of these results across a 
population of 1 million individuals would equate to the 
prevention of about 165 strokes annually and save the 
health service 4790 hospital bed-days, with monetary 
savings of £1·12 million. For the UK as a whole, this would 
prevent about 10 000 strokes annually, and would generate 
savings of 290 000 hospital bed-days and monetary savings 
of £68 million in acute care costs alone. In addition, the 
reductions in disability rates at 6 months might lead to a 
reduction in the long-term usage of the health service in 
the community. The phase 2 clinic costs, which are not 
included in these results, are likely to be a small proportion 
of the savings. 
This rigorous study investigated the eﬀ ect of urgent 
assessment and treatment of TIAs and strokes that do not 
require immediate admission to hospital on hospital 
admissions, hospital bed-days, and the associated costs. As 
discussed in the main EXPRESS study paper,15 the random 
assignment of individuals was not feasible because 
patients would not consent to delayed specialist assessment 
and treatment. Nevertheless, we would argue that the 
EXPRESS study produced results that are reliable and 
convincing, and that EXPRESS should not be confused 
with studies that have historical controls (ie, the control 
group is chosen retrospectively), which have the potential 
for incomplete ascertainment of cases and the introduction 
of selection bias. By contrast, the control group in the 
EXPRESS study was prospectively recruited in phase 1 and 
included all patients who presented for medical attention 
in the whole study population, which minimised any 
potential for selection bias. 
There was also little evidence of other sources of bias.15 
First, there was no signiﬁ cant temporal change in the rates 
of referral to the EXPRESS clinic. Second, there was no 
change in the delay before seeking medical attention after 
a TIA or minor stroke or in the number of patients who 
had early recurrent stroke before seeking medical attention. 
Third, there was no change in the methods (or eﬃ  ciency) 
of either our face-to-face follow-up of patients or our daily 
ascertainment of all strokes in the population. Fourth, 
there was no change in our deﬁ nition of recurrent stroke, 
and all outcomes were independently audited at the end of 
the study by assessors who were blinded to the phase of 
the study. 
There was also no evidence of confounding by factors 
that in addition to the study intervention had changed 
between phase 1 and phase 2. We have reliable evidence of 
stability in the early risk of recurrent stroke in our study 
population, which we have studied over the past two 
decades by comparison of phase 1 of the study with a 
similar population-based study in the same primary care 
practices done between 1981 and 1986.15 The recurrence 
rates in phase 2 changed immediately in October, 2004, 
when the new clinic was introduced, rather than slowly 
over the 5 years of the study. There was also no substantial 
change in the characteristics of the patients who presented 
with TIA or stroke between the two periods, apart from a 
small increase in the proportion on premorbid statin 
treatment, mainly because of the re-presentation of 
patients who were treated in phase 1. Additionally, we 
found attendance at the phase 2 clinic to be signiﬁ cantly 
associated with a reduction in days in hospital, costs of 
admission to hospital, and progression to disability or 
death, after controlling for other baseline characteristics in 
multivariate analyses.
Although the treatment eﬀ ect was large (an 80% relative 
reduction in 90-day risk of stroke), an eﬀ ect of this size 
was consistent with previous studies that modelled the 
probable eﬀ ect of combined treatment modalities on 
secondary prevention after TIA or stroke,9 and was 
plausible in light of the substantial diﬀ erence in delay to 
prescription of treatment between the two phases of 
EXPRESS.15 The median time from the seeking of medical 
attention to ﬁ rst prescription of one of the treatments 
recommended in the faxed letter from the study clinic to 
the primary-care physician in phase 1 (statin, blood 
pressure-lowering drug, clopidogrel, or warfarin) was 
19 (IQR 6–48) days. The equivalent delay in phase 2 was 
1 day (0–3 days; p<0·0001) because treatment was initiated 
in the study clinic.15 Therefore, this study compared 
intensive treatment with minimal treatment during the 
ﬁ rst few high-risk days and weeks after TIA and minor 
ischaemic stroke. Furthermore, in contrast with the 
populations recruited in most randomised controlled 
trials,25 our population-based study included many older 
patients (a third were ≥80 years). 
However, our study did have some limitations in addition 
to being non-randomisied. External biases, such as 
changes in health policy or management between the two 
phases, in theory could explain the reductions in hospital 
stay and associated costs. However, we found that hospital 
admissions for non-recurrent stroke, length of stay, and 
costs did not diﬀ er between phases, and for patients who 
presented directly to hospital inpatient services, rather 
than to the EXPRESS study clinic, patterns of resource use 
were the same during the two phases.
We assessed hospital-related costs and disability only 
over a short period (ie, 90 days and 6 months after an 
event, respectively). As a result, the long-term consequences 
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of urgent assessment and treatment are unknown. The 
90-day follow-up period for resource use was chosen to be 
consistent with the duration of follow-up in the 
eﬀ ectiveness study,15 whereas the 6-month follow-up 
period for disability was used because mRS data were not 
collected at 90 days because recovery from stroke often 
continues beyond 90 days. Published studies have also 
shown that most of the costs of admission to hospital are 
accrued in the months shortly after stroke, and the costs of 
further admissions to hospital are small.26–29 
Process of care outcomes, such as hospital admission, 
are potentially more prone to bias in non-randomised 
studies (or non-blinded randomised studies) because such 
decisions might be inﬂ uenced by knowledge of previous 
treatments. For example, physicians in phase 2 could have 
worked harder not to admit patients with symptoms of 
minor stroke to hospital; however, as shown in table 4, 
overall rates of admissions to hospital were similar in both 
phases. Only admissions to hospital for recurrent stroke 
were signiﬁ cantly lower in phase 2 than they were in 
phase 1, which was because of signiﬁ cantly fewer recurrent 
strokes in phase 2. Of the six recurrent strokes in phase 2, 
ﬁ ve patients (83%) were admitted to hospital, compared 
with 25 of 32 patients (78%) with recurrent stroke in 
phase 1; in fact, admissions for reasons other than 
recurrent stroke were non-signiﬁ cantly higher in phase 2 
(table 4).
To assess the eﬀ ect of the EXPRESS study clinic 
intervention on outcome in patients with TIA and minor 
stroke, our primary analysis was restricted to 591 patients 
who were referred to the study clinic, and excluded 
375 patients with TIA or minor stroke who were referred 
elsewhere (mainly to an emergency department or for 
acute admission to hospital). However, we also did a 
sensitivity analysis that included all patients with TIA or 
minor stroke, which showed reductions in the 90-day risk 
of recurrent stroke in phase 2 compared with phase 1 and 
the number of patients that progressed to death or 
disability at 6 months. However, in phase 2, the reductions 
in hospital bed-days for vascular causes and the associated 
costs were no longer statistically signiﬁ cant, which is not 
unexpected in light of the dilution of the eﬀ ect of the study 
intervention by the inclusion of additional patients who 
were admitted directly to hospital after their initial TIA or 
stroke. 
We did not quantify the costs to the health service of 
setting up outpatient clinics for the urgent assessment 
and treatment of TIA and minor stroke. The phase 2 clinic 
was set up as part of the OXVASC research study, and 
what part of these costs might be incurred in routine 
practice to reduce waiting times for patients with TIA or 
minor stroke was not clear. However, OXVASC did not 
incur any additional costs during phase 2 in terms of 
additional clinical staﬀ  or administrative support. The only 
observable additional cost during phase 2 was the cost of 
the extra medication, because patients in this phase were 
started on medication earlier than were the patients in 
phase 1. Nevertheless, the introduction of outpatient 
clinics would involve additional costs to the health service. 
Recent guidelines published by the UK National Institute 
for Health and Clinical Excellence (NICE) on stroke and 
TIA management30 cite unpublished evidence that 
outpatient clinics that oﬀ er urgent care and treatment for 
patients with TIA or minor stroke generate additional 
costs of £94 per patient compared with a weekly clinic 
(£410 vs £316). Therefore, if the additional cost of setting 
up an EXPRESS phase 2 clinic was similar to that reported 
by NICE, these additional costs would not negate the 
savings in hospital bed-days and costs (£624 per patient) 
associated with urgent assessment and treatment of 
patients with TIA and minor stroke, or the potential 
savings in community care costs due to reduced disability 
rates. In addition, even if the eﬀ ectiveness of the phase 2 
clinic in reducing 90-day recurrent stroke risk were to fall 
to 40%, the additional costs of setting up the phase 2 clinic 
would not negate the savings of £212 per patient in the 
costs of treatment in hospital that are generated by the 
urgent assessment clinic. 
Our results are likely to be conservative because, in 
current average UK practice, many patients with TIA and 
minor stroke wait more than 14 days to be assessed, 
investigated, and treated,14 compared with the 3-day delay 
between ﬁ rst event and specialist assessment in phase 1 of 
EXPRESS.15
In conclusion, we show that, irrespective of the 
characteristics of patients, early assessment and initiation 
of treatment in patients with TIA or minor stroke not only 
reduced the risk of early recurrent stroke by 80%, but also 
reduced hospital admissions, hospital bed-days, costs of 
acute admissions to hospital, and disability rates in patients 
referred to the outpatient specialist clinics. Further follow-
up is needed to assess the long-term outcome, costs, and, 
therefore, long-term cost-eﬀ ectiveness of early assessment 
and treatment, but these short-term results suggest that a 
service provision for TIA and minor stroke that is similar 
to that in phase 2 of the EXPRESS study is likely to be cost-
eﬀ ective. 
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